Clinical trials: in Venezuela
Myocardial Infarction
Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)
The core and extension studies assessed the safety and efficacy of aliskiren when added to optimized standard therapy in patients that have had a high risk acute myocardial infarction (heart attack).
- Trial name
- NCT00414609
- Testing
- Aliskiren
- Where
- 23 sites in United States, Argentina and 21 more
- Volunteers
- 820 people
- Sponsor
- Novartis
Acute Bipolar Depression
Efficacy and Safety of Quetiapine Versus Quetiapine Plus Lithium in Bipolar Depression
The purpose of this study is to compare the efficacy of quetiapine fumarate monotherapy with quetiapine fumarate in combination with lithium in the treatment of a major depressive episode in patients with bipolar disorder.
- Trial name
- QUALITY (NCT00883493)
- Testing
- Quetiapine fumarate XR, Lithium carbonate
- Where
- 24 sites in Argentina, Brazil and 7 more
- Volunteers
- 421 people
- Sponsor
- AstraZeneca
Bipolar Disorders
Study of the Clinical Management of Bipolar Disease
This study is to provide reliable information on the management of bipolar disorders in real every day, clinical practice, to determine the clinical outcomes of such management and use of resources in relation to the disease, and…
- Trial name
- WAVE bd (NCT01062607)
- Where
- 213 sites in Austria, Belgium and 8 more
- Volunteers
- 2,965 people
- Sponsor
- AstraZeneca
Opioid-induced Constipation
Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.
This study will evaluate the safety and efficacy of Tegaserod in opioid-induced constipation in patients with non-cancer pain. Patients who enter this study PRIOR to the core study (CHTF919N2201) interim analysis receive the…
- Trial name
- NCT00414024
- Testing
- Tegaserod
- Where
- 6 sites in United States, China and 4 more
- Volunteers
- 11 people
- Sponsor
- Novartis
Bone Loss, Breast Cancer
Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.
Post-menopausal breast cancer patients will receive letrozole 2.5 mg daily for the treatment of breast cancer and will be randomized to a treatment group to receive either upfront zoledronic acid 4 mg IV 15-minute infusion every…
- Trial name
- NCT00171340
- Testing
- Zoledronic acid, Letrozole
- Where
- 106 sites in Argentina, Australia and 26 more
- Volunteers
- 1,065 people
- Sponsor
- Novartis Pharmaceuticals
Idiopathic Menorrhagia
MiCo - Mirena or Conventional Medical Treatment for Menorrhagia
The aim of this prospective, non-interventional post-marketing surveillance study is to obtain data on safety and efficacy of Mirena in treatment of heavy menstrual bleeding (Menorrhagia) under daily-life treatment conditions.For…
- Trial name
- NCT01085487
- Testing
- Levonorgestrel (Mirena, BAY86-5028), Hormonal treatment, Antifibrinolytic treatment
- Where
- 14 sites in Albania, Bosnia and Herzegovina and 12 more
- Volunteers
- 1,211 people
- Sponsor
- Bayer
Carcinoma, Renal Cell
Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
The primary objective of this protocol is to provide access to SU011248 treatment for patients with metastatic RCC who are ineligible for participation in ongoing SU011248 clinical studies and have the potential to derive…
- Trial name
- NCT00130897
- Testing
- Sutent
- Where
- 271 sites in United States, Argentina and 48 more
- Sponsor
- Pfizer
Gastrointestinal Neoplasm
A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248
The purpose of this study is to permit access to SU011248 for treatment use by patients with GIST given the following conditions: a) patients undergo screening, but are not eligible for participation in ongoing clinical studies…
- Trial name
- NCT00094029
- Testing
- Sutent
- Where
- 118 sites in United States, Argentina and 32 more
- Sponsor
- Pfizer
Hypertension
Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension
This study will compare the safety and efficacy of initial combination treatment with aliskiren + amlodipine to sequential add-on treatment strategies with aliskiren or amlodipine in patients with hypertension.
- Trial name
- ACCELERATE (NCT00797862)
- Testing
- Amlodipine, hydrochlorothiazide, Aliskiren
- Where
- 10 sites in Canada, Costa Rica and 8 more
- Volunteers
- 1,254 people
- Sponsor
- Novartis
Hypertension
Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal
This study was specifically designed to provide additional information on the mechanism of action of direct renin inhibition postulating the higher-level RAS cascade inhibition.
- Trial name
- ASSERTIVE (NCT00865020)
- Testing
- Aliskiren, Telmisartan
- Where
- 16 sites in Brazil, Canada and 14 more
- Volunteers
- 822 people
- Sponsor
- Novartis
Hypertension
Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone
This study will assess the safety and efficacy of combination aliskiren/amlodipine in patients not adequately controlled with aliskiren alone
- Trial name
- NCT00777946
- Testing
- Aliskiren 300 mg, Aliskiren/Amlodipine 300/5 mg, Aliskiren/Amlodipine 300/10 mg
- Where
- 9 sites in Estonia, France and 7 more
- Volunteers
- 818 people
- Sponsor
- Novartis
Bronchitis, Chronic
A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Acute Symptoms of Chronic Bronchitis
This study was performed to confirm that a single 2.0-g dose of azithromycin SR is at least as effective as 7 days of levofloxacin 500 mg/day in adults with acute exacerbation of chronic bronchitis Secondary objectives: To assess…
- Trial name
- NCT00644449
- Testing
- azithromycin SR (Zithromax; compound: CP-62,993), levofloxacin
- Where
- 75 sites in United States, Brazil and 11 more
- Volunteers
- 551 people
- Sponsor
- Pfizer
Hypercholesterolemia, Coronary Heart Disease
12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe
The purpose of this study is to determine whether treatment of Rosuvastatin (CRESTOR™) or Simvastatin given as monotherapy or given in combination with Ezetimibe, will lower the Low Density Lipoprotein Cholesterol (LDL-C) in…
- Conditions
- Hypercholesterolemia, Coronary Heart Disease, Atherosclerosis
- Trial name
- GRAVITY (NCT00525824)
- Testing
- Rosuvastatin (Crestor), Ezetimibe, Simvastatin
- Where
- 9 sites in United States, Argentina and 7 more
- Volunteers
- 1,743 people
- Sponsor
- AstraZeneca
HIV Infections
A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine
The purpose of this study is to compare the effectiveness of treatment with BMS-232632 to that of efavirenz (EFV) when both are used with zidovudine (ZDV) and lamivudine (3TC).
- Trial name
- NCT00013897
- Testing
- Atazanavir, Lamivudine/Zidovudine, Efavirenz
- Where
- 99 sites in United States, Austria and 22 more
- Sponsor
- Bristol-Myers Squibb
Acute Bronchial Obstruction, Asthma
Efficacy of Formoterol vs Ipatropioum Bromide Plus Fenoterol in Children (5-<12 Years) With Acute Bronchial Obstruction
To determine efficacy and tolerability of inhaled Formoterol vs nebulized Ipatropioum Bromide plus Fenoterol in cumulative sequential doses in asthmatic children (5-<12 years) with acute bronchial obstruction attending emergency…
- Trial name
- NCT00460577
- Testing
- Formoterol fumerate, fenoterol/ipratropium bromide
- Where
- 2 sites in Venezuela
- Volunteers
- 60 people
- Sponsor
- Novartis
Hypertension
Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy
Primary Objective: To demonstrate that the antihypertensive efficacy of the fixed combination irbesartan/amlodipine 150/5 mg is superior to that of amlodipine 5 mg monotherapy in lowering systolic blood pressure (SBP) as measured…
- Trial name
- I-COMBINE (NCT00956644)
- Testing
- irbesartan/amlodipine, amlodipine
- Where
- 40 sites in Brazil, Chile and 7 more
- Volunteers
- 406 people
- Sponsor
- Sanofi
Hypertension
Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy
Primary Objective: To demonstrate that the antihypertensive efficacy of the fixed combination irbesartan/amlodipine 300/5 mg is superior to that of irbesartan 300 mg monotherapy in lowering systolic blood pressure (SBP) as…
- Trial name
- I-ADD (NCT00957554)
- Testing
- irbesartan/amlodipine, irbesartan
- Where
- 38 sites in Brazil, Colombia and 6 more
- Volunteers
- 435 people
- Sponsor
- Sanofi
Chronic Obstructive Pulmonary Disease
A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD
The purpose of this study is to determine if SYMBICORT® delivered via a pressurized metered-dose inhaler, referred to as a pMDI, is effective in preventing COPD exacerbations.
- Trial name
- NCT00419744
- Testing
- Budesonide/formoterol (SYMBICORT) pMDI, Formoterol Turbuhaler
- Where
- 140 sites in United States, Argentina and 7 more
- Volunteers
- 1,200 people
- Sponsor
- AstraZeneca
Smoking Cessation
Assessment of Safety and Efficacy of Varenicline in Patients That Wish to Stop Smoking
The primary objective of this protocol is to evaluate 12 weeks of treatment of varenicline compared to placebo for smoking cessation.
- Trial name
- NCT00594204
- Testing
- varenicline tartrate (CP-526, 555-18)
- Where
- 42 sites in Brazil, Colombia and 9 more
- Volunteers
- 593 people
- Sponsor
- Pfizer
Hypertension
ACTUAL: Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination
To compare the antihypertensive efficacy of the combination irbesartan/hydrochlorothiazide (HCTZ) using either a usual or an active elective titration regimen.
- Trial name
- ACTUAL (NCT00708344)
- Testing
- Irbesartan - Hydrochlorothiazide
- Where
- 16 sites in Algeria, Argentina and 14 more
- Volunteers
- 832 people
- Sponsor
- Sanofi